KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Raw Materials (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Raw Materials for 15 consecutive years, with $21.9 million as the latest value for Q4 2025.

  • Quarterly Raw Materials fell 8.94% to $21.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $21.9 million through Dec 2025, down 8.94% year-over-year, with the annual reading at $21.9 million for FY2025, 8.94% down from the prior year.
  • Raw Materials for Q4 2025 was $21.9 million at Halozyme Therapeutics, up from $19.0 million in the prior quarter.
  • The five-year high for Raw Materials was $30.6 million in Q3 2024, with the low at $6.0 million in Q1 2021.
  • Average Raw Materials over 5 years is $18.2 million, with a median of $18.7 million recorded in 2025.
  • The sharpest move saw Raw Materials soared 137.5% in 2023, then plummeted 37.99% in 2025.
  • Over 5 years, Raw Materials stood at $10.7 million in 2021, then increased by 29.24% to $13.8 million in 2022, then soared by 71.45% to $23.6 million in 2023, then grew by 1.56% to $24.0 million in 2024, then dropped by 8.94% to $21.9 million in 2025.
  • According to Business Quant data, Raw Materials over the past three periods came in at $21.9 million, $19.0 million, and $17.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.